The Somascan® Assay: Biomarker Discovery to Delivery | Virtual Event

As part of the Molecular Medicine Tri-Con virtual conference on February 16, 2021, Dr. Sheri Wilcox of SomaLogic described how the SomaScan Assay has been used to identify protein patterns as surrogates for clinical outcomes, discover proteins associated with disease states, and correlate protein measurements with genetic variants.

Watch the webinar now

ABSTRACT

The SomaScan Assay is a proteomic platform that uses single-stranded DNA engineered with aromatic hydrocarbon side chains for binding to protein targets. The SomaScan Assay has been used to identify signals as surrogates for clinical outcomes, discover proteins associated with disease states, and correlate protein measurements with genetic variants.

Sheri K. Wilcox, Ph.D

Scientific Liaison and Technical Services, SomaLogic Inc

Sheri K. Wilcox is Senior Director, Scientific Liaison and Technical Services, at SomaLogic, Inc. in Boulder, Colorado. She received her B.S. in Chemistry from Vanderbilt University in Nashville, Tennessee, in 1993 and her Ph.D. in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, California, in 1999. She completed two years of post-doctoral studies at Pharmacia and Upjohn in Kalamazoo, Michigan, and then joined SomaLogic, Inc. in 2001, where she has been contributing to the generation and utility of novel protein affinity reagents based on Slow-Off rate Modified Aptamers (SOMAmer® reagents) for over 19 years.

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email